News & Media


Amorsa Therapeutics Appoints Jeffrey Wiesen to Board of Directors

Southborough, MA, June 1, 2018 – Amorsa Therapeutics Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, is pleased to announce the appointment of Jeffrey Wiesen to its Board of Directors. As the former Chair of Mintz Levin’s Life Sciences Practice, Jeff has been a leader in the biotechnology industry since its inception and has actively assisted numerous companies ranging from newly formed start-up ventures to public pharmaceutical companies. “We are thrilled to welcome Jeff to our Board,” said Joe Blanchard, President and Chief Executive Officer of Amorsa. “Jeff is an industry veteran and has More


Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds

Southborough, MA, January 9, 2018 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, announced today that its patent application for oral compositions of ketamine and related compounds was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The U.S. patent will not expire until after 2033. “This new patent directed toward Amorsa’s anticipated commercial formulations marks another significant accomplishment for the company,” said Dr. Alex Nivorozhkin, COO of Amorsa and co-inventor on this patent. “There’s tremendous commercial potential for Amorsa’s technology to treat several nervous More


Amorsa Therapeutics Featured in the June Issue of Life Science Leader Magazine

Southborough, MA, June 28, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders today announced that the company was featured in the June issue of Life Science Leader magazine. Please click here to view the article. About Amorsa Therapeutics Amorsa is an early-stage, neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders including moderate-to-severe pain and treatment-resistant depression. Founded in 2013, Amorsa has assembled a leadership team with experience in building several successful life science companies and has a strong track record in developing novel therapeutic treatments.  More


Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-­‐Resistant Depression

Southborough, MA, January 5, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate for treatment-resistant depression based on Amorsa’s proprietary ketamine analog technology. Amorsa’s product candidates are designed to show efficacy as rapidly acting antidepressants with an extended duration of action, possess an attractive side-effect profile, and enable oral dose administration. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, Amorsa will receive an upfront payment, More


Amorsa Therapeutics Appoints Anita Gupta, D.O., Pharm.D., to its Board of Directors

Littleton, MA., Nov. 1, 2016 – Amorsa Therapeutics, a neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders, is pleased to announce today that Anita Gupta, D.O., Pharm.D., has been appointed to Amorsa’s Board of Directors. “We are extremely proud to welcome Anita to our Board,” said Joe Blanchard, President and Chief Executive Officer of Amorsa. “Anita’s contributions to the field have been instrumental to the continued advancement of improved treatment options for neurological diseases. Her extensive drug development experience, along with her broad regulatory, clinical, and strategic insight will be invaluable to Amorsa.” Dr. Gupta More


Amorsa Therapeutics Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences Littleton, MA, Feb. 1, 2016 — Amorsa Therapeutics, a preclinical stage, neuropharmaceutical company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish More